{"entity":{"id":"da-front-anti-amyloid","kind":"section","name":"Anti-amyloid treatment","aka":[],"tldr":"Antibodies that lower amyloid plaques in early symptomatic Alzheimer’s disease, with ARIA monitoring.","summary":"Lecanemab and donanemab are the current US-approved examples. They need amyloid confirmation, infusion capacity, and MRI. They are not indicated for vascular, Lewy body, or frontotemporal dementia as disease-modifying care.","asOf":"2026-09-21","links":[{"label":"FDA Leqembi","url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"}],"tags":["dementia-atlas"],"related":["da-lecanemab","da-donanemab"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"order":5},"route":"/fronts/da-front-anti-amyloid/","neighbours":{"drug":[{"id":"da-donanemab","kind":"drug","name":"Donanemab","route":"/drugs/da-donanemab/"},{"id":"da-lecanemab","kind":"drug","name":"Lecanemab","route":"/drugs/da-lecanemab/"}],"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"technology":[{"id":"da-tech-anti-amyloid-mab","kind":"technology","name":"Anti-amyloid antibodies","route":"/technologies/da-tech-anti-amyloid-mab/"}]}}